Diagnosis with a little brush

“Three researchers from the University of Bologna have developed a technology that enables early diagnosis of oral cancer. A noninvasive and painless system that also has potential applications related to prognosis and follow-up with a strong social impact. – Forbes, Italian edition, August 2022 Great advances in personalized medicine are revolutionizing the approach to the patient. In particular, the development of next-generation drugs, methods of early diagnosis, correct prognosis, prediction of efficacy, and personalized therapy represent a new frontier in medicine. Oral carcinoma remains one of the most aggressive cancers worldwide, with a 50% mortality rate within the first 5 years…

Innovation in Molecular Diagnostics

Headquartered in Bologna, Italy, Studium Genetics is a spin-off company of Alma Mater Studiorum – University of Bologna that develops early diagnosis and prognosis predictive methods in the molecular oncology field, with particular regard to oral cancer. Studium Genetics is a company focused on precision medicine by a groundbreaking genomic and epigenomic testing, which generate reliable clinical data about the biology of each patient with cancer or neurological disorders. Backed by prestigious physicians and institutions, we aim at shifting the standard of care towards more innovative treatments. We focus our attention on epigenetic biomarkers, which have significantly contributed to improved diagnostic…